Blood-Based Protein Signature Predicts Organ-Specific Aging and Disease Risk, Stanford Study Shows
核心洞察
Stanford Medicine researchers developed a blood-based indicator that assesses the biological age of 11 organ systems using nearly 3,000 proteins from over 44,000 UK Biobank participants.
An "extremely aged" brain was associated with a 3.1-fold higher risk of Alzheimer's disease (搜索) and a 182% increased mortality risk over 15 years, while a "youthful" brain reduced mortality risk by 40%.
The algorithm can predict organ-specific disease risk up to a decade in advance, potentially enabling preventive interventions before symptoms emerge.
A team of Stanford Medicine investigators has developed a blood-based algorithm capable of measuring the biological age of 11 distinct organ systems and predicting an individual's future risk of organ-specific diseases—including Alzheimer's, heart failure (搜索), and chronic obstructive pulmonary disease (搜索)—up to a decade before symptoms appear.
The research, published July 9 in Nature Medicine, analyzed blood samples from 44,498 randomly selected UK Biobank participants aged 40 to 70, tracking their health outcomes over up to 17 years. Using an advanced proteomics platform, the team measured levels of nearly 3,000 proteins in each participant's blood, approximately 15% of which could be traced to single-organ origins.
"We've developed a blood-based indicator of the age of your organs," said Tony Wyss-Coray, PhD, professor of neurology and neurological sciences and director of the Knight Initiative for Brain Resilience at the Wu Tsai Neurosciences Institute. "With this indicator, we can assess the age of an organ today and predict the odds of your getting a disease associated with that organ 10 years later."
How the Organ-Aging Clock Works
The researchers fed participants' blood-borne protein levels into a computer model, determining average levels of organ-specific proteins adjusted for chronological age. From this, they generated an algorithm that calculated how much each individual's composite protein "signature" for a given organ deviated from the age-adjusted average.
Organs with protein signatures deviating more than 1.5 standard deviations from the mean were classified as "extremely aged" or "extremely youthful." Approximately one-third of study participants had at least one organ falling into these extreme categories, and one in four had multiple extremely aged or youthful organs.
The 11 organ systems assessed included the brain, muscle, heart, lung, arteries, liver, kidneys, pancreas, immune system, intestine, and fat.
Brain Age as the Gatekeeper of Longevity
Among all organs examined, brain biological age emerged as the single most powerful predictor of overall mortality. Having an extremely aged brain increased subjects' risk of dying by 182% over a roughly 15-year period, while individuals with extremely youthful brains experienced a 40% reduction in mortality risk over the same duration.
"The brain is the gatekeeper of longevity," Wyss-Coray said. "If you've got an old brain, you have an increased likelihood of mortality. If you've got a young brain, you're probably going to live longer."
The association between brain age and Alzheimer's disease (搜索) was particularly striking. An extremely aged brain conferred a 3.1-fold higher risk of developing Alzheimer's compared to a normally aging brain, while an extremely youthful brain reduced risk to barely one-fourth that of normal. In practical terms, someone with a biologically old brain is approximately 12 times as likely to receive a new Alzheimer's diagnosis over the next decade as someone the same age with a biologically young brain.
Organ-Specific Disease Prediction
The strongest disease associations aligned predictably with the corresponding organ: an extremely aged heart predicted higher risk of atrial fibrillation (搜索) or heart failure (搜索), aged lungs predicted heightened COPD risk, and an old brain predicted elevated Alzheimer's risk. However, risks for several diseases were also influenced by the biological age of multiple different organs, suggesting interconnected aging processes across organ systems.
From Sick Care to Health Care
Wyss-Coray envisions this approach as a paradigm shift in medicine. "Today, you go to the doctor because something aches, and they take a look to see what's broken. We're trying to shift from sick care to health care and intervene before people get organ-specific disease," he said.
The test could become available within the next two to three years. "The cost will come down as we focus on fewer key organs, such as the brain, heart and immune system, to get more resolution and stronger links to specific diseases," Wyss-Coray noted.
Medical researchers may use extreme brain age as a proxy for impending Alzheimer's disease (搜索), enabling intervention before outward symptoms manifest. Clinical trials combining organ-age assessments with careful collection of lifestyle, diet, and medication data could illuminate which interventions slow organ-specific aging and whether existing approved drugs can restore organ youth.
Cell-Type-Level Aging Reveals New Insights
In a companion study published June 15, 2026, also in Nature Medicine, Wyss-Coray and colleagues extended the research to individual cell types within organs. This work revealed that individuals carrying two copies of the APOE4 (搜索) genotype—who are at extremely high risk for Alzheimer's disease (搜索)—tend to have "older" astrocytes, key support cells in the brain. However, among double-dose APOE4 carriers whose astrocytes lean toward the "youthful" side, the amplified genetic risk is effectively neutralized.
The same study found that amyotrophic lateral sclerosis (搜索) (ALS) incidence is 12.7 times higher among individuals with an "aged" skeletal-muscle-cell profile compared to those with "youthful" muscle cells—a difference detectable more than three years before any symptom-based diagnosis.
Commercialization Pathway
Wyss-Coray is a co-founder and scientific officer of Teal Omics (搜索) and Vero Bioscience (搜索), two companies to which Stanford University's Office of Technology Licensing has licensed the technology for commercializing screens for new drug targets and a consumer product, respectively. The analytical tool is currently available only for research purposes.
The study was funded by the National Institutes of Health, the Milky Way Foundation, the Knight Initiative for Brain Resilience, and the Stanford Alzheimer's Disease (搜索) Research Center.